{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-To-Moderate+Alzheimer%27s+Disease&page=3",
    "query": {
      "condition": "Mild-To-Moderate Alzheimer's Disease",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 199,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-To-Moderate+Alzheimer%27s+Disease&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-To-Moderate+Alzheimer%27s+Disease&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T15:30:22.030Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02079246",
      "title": "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Idalopirdine 60 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1463,
      "start_date": "2014-04-07",
      "completion_date": "2017-07-06",
      "has_results": true,
      "last_update_posted_date": "2018-08-10",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079246"
    },
    {
      "nct_id": "NCT00174525",
      "title": "Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "AAB-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacology Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": null,
      "start_date": "2005-04",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2012-05-09",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 2,
      "location_summary": "Los Alamitos, California • Northridge, California",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00174525"
    },
    {
      "nct_id": "NCT01712074",
      "title": "Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "PF-05212377 (SAM-760)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2012-11",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 40,
      "location_summary": "Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712074"
    },
    {
      "nct_id": "NCT01716637",
      "title": "Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Life Extension Foundation Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-02",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-12",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 2,
      "location_summary": "Coral Springs, Florida • Delray Beach, Florida",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716637"
    },
    {
      "nct_id": "NCT02036645",
      "title": "SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild-Moderate Alzheimer's Disease",
        "Healthy Elderly"
      ],
      "interventions": [
        {
          "name": "MEDI1814 for IV injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI1814 for Subcutaneous Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IV Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Subcutaneous Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 77,
      "start_date": "2014-02-04",
      "completion_date": "2016-09-15",
      "has_results": true,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 10,
      "location_summary": "Glendale, California • Long Beach, California • Panorama City, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02036645"
    },
    {
      "nct_id": "NCT00812565",
      "title": "Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "octagam 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 58,
      "start_date": "2009-02",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-05-05",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 1,
      "location_summary": "Hoboken, New Jersey",
      "locations": [
        {
          "city": "Hoboken",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00812565"
    },
    {
      "nct_id": "NCT02947893",
      "title": "Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo Capsule(s) Once a Day by Mouth",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib Capsule(s) Once a Day by Mouth",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 37,
      "start_date": "2017-01",
      "completion_date": "2021-03",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947893"
    },
    {
      "nct_id": "NCT03867253",
      "title": "Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild to Moderate Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ORY-2001 Low dose",
          "type": "DRUG"
        },
        {
          "name": "ORY-2001 High dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oryzon Genomics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-05-16",
      "completion_date": "2020-11-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 4,
      "location_summary": "Wellington, Florida • Columbus, Georgia • Princeton, New Jersey + 1 more",
      "locations": [
        {
          "city": "Wellington",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Willow Grove",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867253"
    },
    {
      "nct_id": "NCT01782742",
      "title": "Bexarotene Amyloid Treatment for Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Bexarotene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-02",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-12",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01782742"
    },
    {
      "nct_id": "NCT01466088",
      "title": "Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "AZD3480",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Targacept Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 386,
      "start_date": "2011-10",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-10-08T15:30:22.030Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01466088"
    }
  ]
}